Last reviewed · How we verify
Raphamin
Raphamin is a Small molecule drug developed by Materia Medica Holding. It is currently in Phase 3 development. Also known as: MMH-407.
Raphamin is a drug developed by Materia Medica, a Russian company, as an antiviral. It has been studied in clinical trials for various conditions, including Acute Respiratory Viral Infection, Cystitis Chronic, Cystitis Bacterial, Recurrence of Chronic Bacterial Cystitis, and Influenza.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Raphamin |
|---|---|
| Also known as | MMH-407 |
| Sponsor | Materia Medica Holding |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients (PHASE3)
- Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years (PHASE3)
- Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis (PHASE3)
- Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia (PHASE3)
- Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients (PHASE3)
- Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old (PHASE3)
- Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults (PHASE3)
- Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Raphamin CI brief — competitive landscape report
- Raphamin updates RSS · CI watch RSS
- Materia Medica Holding portfolio CI
Frequently asked questions about Raphamin
What is Raphamin?
Who makes Raphamin?
Is Raphamin also known as anything else?
What development phase is Raphamin in?
Related
- Manufacturer: Materia Medica Holding — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: MMH-407
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing